Drugs / Quercetin
Quercetin
also known as
3'-hydroxykaempferol · 3, 30, 40, 5, 7-pentahydroxyflavone · 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one · C.i. 75670 · C.i. natural red 1 · Corvitin · Cyanidenolon 1522 · Korvitin · +15 more
Small molecule targets MMP12, MMP9, PLAUR via inhibition
Trials 46 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT07025226 | Aug 2025 → Sep 2027 expected | glioma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 0 | NCT05680662 | Jan → Dec 2023 | female breast carcinoma, triple-negative breast carcinoma | Ministry of Health, Saudi Arabia | Unknown | No outcome recorded |
| Phase 0 | NCT04853199 | Jun → Jul 2021 | severe acute respiratory syndrome | Hôpital Universitaire Sahloul | Completed | No outcome recorded |
| Phase 0 | NCT02989129 | Apr 2018 → Apr 2020 | chemotherapy-induced neuropathy | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 0 | NCT01722669 | May 2012 → Dec 2019 | — | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 111 trials | ||||||
| Phase 1 | NCT07628972 | May 2026 → Sep 2028 expected | dyskeratosis congenita, telomere syndrome | Children's Hospital Medical Center, Cincinnati | Recruiting | No outcome recorded |
| Phase 1 | NCT07433621 | Feb 2026 → Nov 2028 expected | X-linked lymphoproliferative disease due to XIAP deficiency | Children's Hospital Medical Center, Cincinnati | Recruiting | No outcome recorded |
| Phase 1 | NCT07270120 | Jan 2026 → Jan 2027 expected | secondary progressive multiple sclerosis | Ohio State University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06775392 | Jan → Aug 2024 | periodontal disorder | Krishnadevaraya College of Dental Sciences & Hospital | Completed | No outcome recorded |
| Phase 1 | NCT06209229 | May 2022 → May 2023 | non-small cell lung carcinoma | MIPO Clinic | Completed | No outcome recorded |
| Phase 1 | NCT04851821 | Jan → May 2021 | COVID-19 | Hôpital Universitaire Sahloul | Completed | No outcome recorded |
| Phase 1 | NCT02874989 | Dec 2016 → Jun 2019 | idiopathic pulmonary fibrosis | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 1 | NCT02652052 | Mar 2016 → May 2023 | disease related to hematopoietic stem cell transplant | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT02226484 | Aug 2014 → May 2016 | gastroesophageal reflux disease | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 1 | NCT01912820 | Jan 2014 → Jan 2016 | prostate adenocarcinoma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01720147 | Jul 2012 → Oct 2021 | Fanconi anemia | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06615752 | Oct 2026 → Apr 2028 expected | prostate carcinoma | Charles Drew University of Medicine and Science | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04785300 | Jul 2022 → Dec 2026 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05422885 | May 2022 → Jan 2024 | premature aging syndrome | Lewis Lipsitz | Completed | No outcome recorded |
| Phase 1/2 | NCT04063124 | Feb 2020 → Dec 2021 | Alzheimer disease | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT06683534 | Jul 2026 → Dec 2030 expected | obesity disorder, vascular insufficiency disorder | Medical College of Wisconsin | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07144293 | Dec 2025 → Sep 2026 expected | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07182526 | Sep 2025 → May 2026 overdue | polycystic ovary syndrome | Al-Mustansiriyah University | Recruiting | No outcome recorded |
| Phase 2 | NCT06940297 | Jun 2025 → Aug 2031 expected | plasma cell myeloma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT06982248 | Aug 2024 → Feb 2025 overdue | periodontal disorder | Mansoura University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06470061 | Jul 2024 → Jul 2027 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Zaparackas and Knepper LTD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06355037 | May → Dec 2024 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05838560 | Jul 2023 → Oct 2027 expected | premature aging syndrome, schizophrenia | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05724329 | Feb 2023 → Apr 2024 overdue | head and neck squamous cell carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05456022 | Jul 2022 → Dec 2023 | oral cavity cancer | Cairo University | Unknown | No outcome recorded |
| Phase 2 | NCT04685590 | Dec 2021 → Jan 2028 expected | cognitive impairment with or without cerebellar ataxia, early-onset autosomal dominant Alzheimer disease | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05062486 | Oct 2021 → Nov 2024 | age-related macular degeneration | Paul A Knepper, MD PhD | Completed | No outcome recorded |
| Phase 2 | NCT04946383 | Dec 2020 → Dec 2021 | — | TruDiagnostic | Unknown | No outcome recorded |
| Phase 2 | NCT04313634 | Jun 2020 → Jun 2023 | — | Sundeep Khosla, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT03476330 | May 2018 → Mar 2025 | Fanconi anemia, squamous cell carcinoma | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 2 | NCT01839344 | May 2013 → Mar 2014 | type 2 diabetes mellitus | Bastyr University | Completed | No outcome recorded |
| Phase 2 | NCT00455416 | Apr 2007 → Apr 2009 | follicular lymphoma | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05653258 | Oct 2023 → Feb 2027 expected | obesity disorder | Cedars-Sinai Medical Center | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06650891 | Oct 2024 → Jan 2025 | — | Future University in Egypt | Completed | No outcome recorded |
| Phase 3 | NCT03943459 | Aug 2019 → Apr 2022 | coronary atherosclerosis | InCor Heart Institute | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT04258410 | Sep 2022 → Dec 2023 | — | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 4 | NCT04468139 | Jun → Jul 2020 | COVID-19 | Ministry of Health, Saudi Arabia | Unknown | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT07466420 | Jan 2026 → Jan 2028 expected | idiopathic pulmonary fibrosis, pulmonary fibrosis | Katerina M. Antoniou | Recruiting | No outcome recorded |
| — | NCT06591767 | Oct 2023 → Apr 2024 | — | Liaquat University of Medical & Health Sciences | Completed | No outcome recorded |
| — | NCT05037240 | Jan → Apr 2021 | COVID-19 | Azienda di Servizi alla Persona di Pavia | Completed | No outcome recorded |
| — | NCT00003365 | Aug 1996 → Jul 2006 | colorectal cancer | University of Medicine and Dentistry of New Jersey | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 10 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05928546 Comparator | Feb → May 2024 | periodontitis | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT01708278 Comparator | Feb 2014 → Oct 2015 | chronic obstructive pulmonary disease | University of Michigan | Completed | No outcome recorded |
| Phase 1 | NCT01375101 Comparator | Apr 2010 → Sep 2011 | atrophic lichen planus, oral erosive lichen | Mashhad University of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05506488 Comparator | Jul 2023 → Feb 2026 | fibrotic liver disease, metabolic dysfunction-associated steatohepatitis | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 1/2 | NCT03989271 Comparator | Oct 2019 → May 2024 | chronic obstructive pulmonary disease | Temple University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01732393 Comparator | Jan 2010 → Oct 2011 | chemotherapy-induced oral mucositis | Mashhad University of Medical Sciences | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06003270 Comparator | Nov 2023 → Feb 2025 | chronic bronchitis, pulmonary emphysema | Temple University | Unknown | No outcome recorded |
| Phase 2 | NCT04733534 Comparator | Jun 2022 → Dec 2026 expected | childhood malignant neoplasm | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04907253 Comparator | Jun 2021 → Dec 2023 | coronary artery disorder | Montreal Heart Institute | Completed | No outcome recorded |
| Phase 2 | NCT02848131 Comparator | Jul 2016 → Apr 2027 expected | chronic kidney disease | Mayo Clinic | Enrolling by invitation | No outcome recorded |
Evidence & citations 28 cited values
Every value below carries the sentence it was read from. 59 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | quercetin | “Quercetin will be provided to take one Quercetin per day for 30 days to look for differences in microvascular function.” NCT06683534 ↗55“hyperuricemic patients (uric acid \> 8 mg/dL) received oral supplemental Quercetin, twice a day for 90 days.” NCT06591767 ↗ “Quercetin from onion juice - take orally 1000 mg in the morning before meals” NCT06209229 ↗ “Quercetin is a flavonol, a subclass of flavonoid compounds.” NCT05037240 ↗ “Quercetin 250 mg capsules; oral single dose of 2000 mg” NCT01839344 ↗ “Dietary Supplement: Quercetin (dietary supplement)” NCT07466420 ↗ |
| Known as | 3'-hydroxykaempferol | ChEMBL registry synonym — accepted as the source's own label CHEMBL50 ↗ |
| Known as | 3, 30, 40, 5, 7-pentahydroxyflavone | “Quercetin (3, 30, 40, 5, 7-pentahydroxyflavone) is a naturally occurring antioxidant that belongs to a group of polyphenolic compounds known as flavonoids.” NCT07628972 ↗ |
| Known as | 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one | “Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one” NCT05456022 ↗ |
| Known as | C.i. 75670 | ChEMBL registry synonym — accepted as the source's own label CHEMBL50 ↗ |
| Known as | C.i. natural red 1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL50 ↗ |
| Known as | Corvitin | ChEMBL registry synonym — accepted as the source's own label CHEMBL50 ↗ |
| Known as | Cyanidenolon 1522 | ChEMBL registry synonym — accepted as the source's own label CHEMBL50 ↗ |
| Known as | Korvitin | ChEMBL registry synonym — accepted as the source's own label CHEMBL50 ↗ |
| Known as | LDN 0052529 | ChEMBL registry synonym — accepted as the source's own label CHEMBL50 ↗ |
| Known as | Lipoflavon | ChEMBL registry synonym — accepted as the source's own label CHEMBL50 ↗ |
| Known as | Meletin | ChEMBL registry synonym — accepted as the source's own label CHEMBL50 ↗ |
| Known as | Nano-QUT | “Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT)” NCT05456022 ↗ |
| Known as | NSC 57655 | ChEMBL registry synonym — accepted as the source's own label CHEMBL50 ↗ |
| Known as | NSC 9219 | ChEMBL registry synonym — accepted as the source's own label CHEMBL50 ↗ |
| Known as | Quercetin (constituent of ginkgo) | ChEMBL registry synonym — accepted as the source's own label CHEMBL50 ↗ |
| Known as | Quercetin 500 mg capsule, NOW pharmacetics | “Quercetin 500 mg capsule, NOW pharmacetics” NCT07182526 ↗ |
| Known as | QUERCETIN DIHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL50 ↗ |
| Known as | Quercetine | ChEMBL registry synonym — accepted as the source's own label CHEMBL50 ↗ |
| Known as | Quercetol | ChEMBL registry synonym — accepted as the source's own label CHEMBL50 ↗ |
| Known as | Quertin | ChEMBL registry synonym — accepted as the source's own label CHEMBL50 ↗ |
| Known as | Quertine | ChEMBL registry synonym — accepted as the source's own label CHEMBL50 ↗ |
| Known as | Sophoretin | ChEMBL registry synonym — accepted as the source's own label CHEMBL50 ↗ |
| Known as | Xanthaurine | ChEMBL registry synonym — accepted as the source's own label CHEMBL50 ↗ |
| Action | Deplete | “Selectively ablating senescent cells using dasatinib plus quercetin” PMID 30616998 ↗ Jan 2019 |
| Modality | Small molecule | “quercetin is one of flavonoids , and having therapeutical anti-inflammatory and antioxidant action” NCT01375101 ↗ |
| Route | Oral | “oral quercetin at 1 of 3 doses twice a day” NCT00003365 ↗ |
| Target | PLAUR | “In male cells, a candidate target of quercetin involves interactions between the receptor PLAUR and its ligands PLAU and SERPINE1.” PMID 40375481 ↗ May 2025 |